We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Blood Test Could Diagnose Schizophrenia and Other Disorders

By LabMedica International staff writers
Posted on 22 Feb 2017
Schizophrenia is a chronic, severe mental disorder that affects approximately 1% of the adult population in the USA and influences how a person thinks, feels, and behaves. More...
The onset of symptoms usually begins between ages 16 and 30. Symptoms can range from visual and auditory hallucinations and movement disorders to difficulty beginning and sustaining activities.

The diagnosis of schizophrenia and similar disorders requires a thorough psychological evaluation and a comprehensive medical exam to rule out other conditions. A patient may be evaluated for six or more months before receiving a diagnosis and beginning treatment, particularly if he or she shows only early signs of the disorder.

Scientists at the University of Maryland have developed a blood test that could help doctors more quickly diagnose schizophrenia and other disorders. They used a discovery-driven approach based on the assumptions that chemical biomarkers relating to oxidative stress could be found in blood, and that they could be measured by common electrochemical instruments.

The team used performed an initial clinical evaluation using serum from 10 people diagnosed with schizophrenia, a mental health disorder that is increasingly linked to oxidative stress. The scientists used an iridium salt, potassium hexachloroiridate (K2IrCl6), to probe serum for reducing activities that can transfer electrons to iridium and thus generate detectable optical and electrochemical signals. They showed that this Ir-reducing assay can detect various biological reductants and is especially sensitive to glutathione (GSH) compared to alternative assays.

The new testing method was able to correctly differentiate the samples of those who had been diagnosed with schizophrenia from those who had no history of the disorder. Deana L. Kelly PharmD, BCPP, a professor of psychiatry and a co-author of study said, “Much emerging data suggests that schizophrenia and other psychiatric disorders may be due, in part, to inflammation and oxidative stress abnormalities. Current methods for measuring these potential biomarkers are not standardized and have many flaws.” The study was published on February 7, 2017, in the journal Analytical Chemistry.


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.